At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 18, 2026 at 13:17 ET
Pfizer reaffirms full-year 2026 guidance following the CFO transition announcement on June 18, 2026. Revenue guidance remains $59.5-$62.5B and adjusted diluted EPS at $2.80-$3.00, unchanged from prior communication. This is a routine confirmation filing with no new material financial data.
- FY2026 revenue guidance reaffirmed at $59.5-$62.5B
- FY2026 adjusted diluted EPS guidance reaffirmed at $2.80-$3.00
- CFO transition announced on June 18, 2026, prompted this reaffirmation
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access